Safety and Efficacy Results Published From Neovasc's REDUCE Study


August 6, 2018—Neovasc Inc. announced the publication of results from the REDUCE study by Francesco Giannini, MD, et al online ahead of print in International Journal of Cardiology.

The multicenter REDUCE clinical registry is evaluating the safety and effectiveness of Neovasc's Reducer device, which received CE Mark approval and has been commercially available in Europe since 2015 for the treatment of refractory angina. Reducer is not currently commercially available in the United States.

The efficacy endpoint was the improvement of quality of life and reduction of angina pectoris symptoms in a real-world cohort of 141 patients with coronary artery disease and chronic refractory angina at three high-volume medical centers in Milan, Italy; Tel Aviv, Israel; and Antwerp, Belgium. The safety endpoint of the study was to evaluate the rate of successful Reducer delivery and deployment in the absence of any device-related events.

According to the company, the findings demonstrated that treatment with the Reducer device was very safe and significantly reduced the severity of angina as measured by the Canadian Cardiovascular Society (CCS) classification, with a mean at baseline of 3.05 ± 0.53 reduced to 1.63 ± 0.98 at follow-up (P < .001).

Overall, results show that 81% of the patients experienced improvement in their angina severity by at least one CCS class, and 45% of the patients became free of any limiting angina as they improved by two or more grades in CCS class. All parameters of quality of life as measured by the Seattle Angina Questionnaire significantly improved (P < .001). These benefits translated into a significant reduction in the mean number of anti-ischemic drugs prescribed, from 2.37 ± 0.97 to 2.17 ± 0.95 (P = .003).

According to the company, the results are consistent with those of the COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) randomized sham-controlled clinical trial. In February 2013, the final results from COSIRA were published by Stefan Verheye, MD, et al in The New England Journal of Medicine (2015;372:519–527).


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.